Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab

Abstract EN

Objectives.

To evaluate methotrexate effect on tumor necrosis factor (TNF) alpha bioactivity during infliximab (IFX) therapy in rheumatoid arthritis (RA) patients and to correlate TNF bioactivity with antibody towards IFX (ATI) development and RA clinical response.

Materials and Methods.

Thirty-nine active women RA patients despite conventional synthetic disease modifying antirheumatic drugs (csDMARDs) requiring IFX therapy were enrolled, and clinical data and blood samples were recorded at baseline (W0) and at 6 weeks (W6), W22, and W54 of IFX treatment.

TNF bioactivity as well as IFX trough and ATI concentrations were assessed on blood samples.

Results.

TNF bioactivity decreased from W0 to W54 with a large range from W22 at the time of ATI detection.

From W22, TNF bioactivity was lower in presence of methotrexate as csDMARD compared to other csDMARDs.

IFX trough concentration increased from W0 to W54 with a large range from W22, similarly to TNF bioactivity.

Methotrexate therapy prevented ATI presence at W22 and reduced TNF bioactivity compared to other csDMARDs (p=0.002).

Conclusion.

This suggests that methotrexate plays a key role in TNF bioactivity and against ATI development.